Therapeutic Role of Glucosamine Sulphate Among Patients with Rheumatoid Arthritis
Abstract
Abstract Views: 112
Rheumatoid Arthritis (RA) is a fatal disease. At present, the prevalence of rheumatoid arthritis (RA) in human beings is approximately 1%. Glucosamine (2-amino-2-deoxy-D-glucose) is a naturally occurring aminomonosaccharide in the human body. It is present abundantly in the cartilage and the connective tissue of human beings. It also originates from glucose in almost every human tissue. The purpose of this research is to evaluate the effect of glucosamine sulphate supplements in patients with rheumatoid arthritis to assess it as a treatment for RA. This study was completed in the duration of 2 months using a randomized control trial study method. Ninety individuals (men and women) participated in this research. The data was collected from Azhar Orthopedics Clinic and Mayo Hospital in Lahore. The sample population was divided into group I, II & III, with 30 patients in each group. Group I was given 500 mg glucosamine sulphate/day, group II was given 1000 mg/day for two months, and group III was a controlled group (it was not supplemented with glucosamine sulphate). To conduct an ESR test, a blood sample was taken from the study population on day 0, 30, and 60. The ESR test readings of the individuals were statistically evaluated to assess the anti-arthritic effect of the glucosamine sulphate supplement. The readings were also used to evaluate a more effective dose of the supplement ranging between 500mg and 1000mg. The results indicated that glucosamine sulphate supplements significantly reduced the ESR levels in patients with rheumatoid arthritis. Furthermore, group I and group II exhibited significant results (p<0.001), indicating a reduction in the ESR levels. Therefore, it was determined that glucosamine sulphate supplementation does exhibit an anti-arthritic effect on rheumatoid arthritis patients.
Downloads
References
Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumaticdrugs: 2016update. Ann Rheumatic Dis. 2017;76(6):960-77. http://dx.doi.org/10.1136/annrheumdis-2016-
Leakey JE, Ali AA, Babb AR, et al. Subchronic toxicity evaluation of glucosamine and glucosamine in combination with chondroitin sulfate in obese Zucker rats. ToxicolAppl Pharma. 2021;412:115371. https://doi.org/10.1016/j.taap.2020.115371
Munir MAA, Aziz M, Mahboob A. Frequency of Rheumatoid Factor Positivity in Patients of Rheumatoid Arthritis Report of 95 cases from Lahore, Pakistan. J Fatima Jinnah Med Uni. 2013;7(4):1-5.
Vasiliadis HS, Tsikopoulos K.Glucosamine and chondroitin for the treatment of osteoarthritis. World J Orthop. 2017;8(1):1-8.
Reginster JYL, Bruyere O, Cooper C. Different glucosamine sulphate products generate different outcomes on osteoarthritis symptoms. Annals Rheumatic Dis. 2018;77(7):e39-e39.
National Center for Complementary and Alternative Medicine, National Institutes of Health. The NIH glucosamine/chondroitin arthritis intervention trial (GAIT). J Pain Palliative Care Pharma. 2008;22(1):39-43.
Setnikar I, Pacini MA, Revel L. Antiarthritic effects of glucosamine sulfate studied in animal models. Arzneimittel-forschung. 1991;41(5):542-5.
Zhu X, Sang L, Wu D, Rong J, Jiang L. Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: a meta- analysis of randomized controlled trials. J Orthop Surgery Res. 2018;13(1):170-180.
Way WK, Gibson KG, Breite AG. Determination of glucosamine in nutritional supplements by reversed-phase ion-pairing HPLC. J Liquid Chroma Related Technol, 2000;23(18):2861-2871.
